Journal of Clinical Oncology, Vol 12, 1821-1826, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study

H Anderson, B Lund, F Bach, N Thatcher, J Walling and HH Hansen
Manchester Lung Tumour Study Group, Wythenshawe Hospital, United Kingdom.

PURPOSE: To evaluate the efficacy and safety of gemcitabine, a pyrimidine antimetabolite with activity against solid tumours. PATIENTS AND METHODS: Eighty-two patients with unresectable stage IIIa to IV non- small-cell lung cancer (NSCLC) were entered. The first 54 patients received gemcitabine 800 mg/m2, and subsequent patients 1,000 mg/m2, as a 30-minute intravenous infusion on days 0, 7, and 14. Courses of therapy were repeated every 28 days. Twenty percent dosage escalation was permitted after course no.1 if World Health Organization (WHO) toxicity was < or = 1. RESULTS: Sixteen (20%; 95% confidence interval [CI], 12% to 31%) of 79 patients assessable for response had independently validated partial responses, with a median duration of 7 months. The overall median survival duration was 7 months. Gemcitabine improved disease-related symptoms (70% patients) and increased WHO performance status (44%). Toxicity was generally mild and reversible. Patients experienced little WHO grade 3 and 4 toxicity, with anemia in four (5%), thrombocytopenia in one (1%), leukopenia in six (7%), and neutropenia in 18 (22%). Infection occurred in nine patients (12%) during the study (four were neutropenic), but there were no episodes of WHO grade 3 or 4 infection. WHO grade 3 and 4 biochemical toxicity occurred with transient elevations of transaminases in 10 patients (12%). Two patients had transient WHO grade 3 elevation of serum creatinine levels, and two developed acute renal failure 4 and 6 weeks after the last dose of gemcitabine. There was no WHO grade 4 symptomatic toxicity. WHO grade 3 vomiting occurred in 31 patients (38%) and grade 3 alopecia in one (1%). Flu-like symptoms were associated with gemcitabine administration in 36 patients (44%). Twenty- six patients (32%) experienced fever (1% WHO grade 3), 33 (40%) ankle edema not associated with cardiac failure, 31 (38%) lethargy, and 11 (13%) dyspnea. CONCLUSION: Gemcitabine is an active new agent in the treatment of NSCLC. This schedule was associated with little alopecia or myelosuppression. Gemcitabine warrants further investigation in other malignancies and in combination with other agents.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. A. Treat, R. Gonin, M. A. Socinski, M. J. Edelman, R. B. Catalano, D. M. Marinucci, R. Ansari, H. H. Gillenwater, K. M. Rowland, R. L. Comis, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer Ann. Onc., October 15, 2009; (2009) mdp352v1. [Abstract] [Full Text] [PDF]

				C. Belani, S Dakhil, D. Waterhouse, C. Desch, D. Rooney, R. Clark, M. Monberg, Z Ye, and C. Obasaju Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer Ann. Onc., January 1, 2007; 18(1): 110 - 115. [Abstract] [Full Text] [PDF]

				F. Ohyanagi, F. Taguchi, T. Horai, K. Kasahara, Y. Takeda, K. Shibata, H. Shirosaki, and M. Nishio Phase II Study of Combination Chemotherapy with Gemcitabine and Irinotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens Jpn. J. Clin. Oncol., September 1, 2006; 36(9): 547 - 551. [Abstract] [Full Text] [PDF]

				K.-H. Cho, Y.-B. Song, I.-S. Choi, E.-H. Cho, J.-W. Choi, Y. M. Ahn, Y. H. Roh, S.-H. Nam, and B.-S. Kim A Phase II Study of Single-Agent Gemcitabine as a Second-Line Treatment in Advanced Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., January 1, 2006; 36(1): 50 - 54. [Abstract] [Full Text] [PDF]

				S. Baka, L. Ashcroft, H. Anderson, M. Lind, P. Burt, R. Stout, I. Dowd, D. Smith, P. Lorigan, and N. Thatcher Randomized Phase II Study of Two Gemcitabine Schedules for Patients With Impaired Performance Status (Karnofsky performance status <= 70) and Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 1, 2005; 23(10): 2136 - 2144. [Abstract] [Full Text] [PDF]

				C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC Ann. Onc., March 1, 2004; 15(3): 410 - 418. [Abstract] [Full Text] [PDF]

				W. Scheithauer, B. Schull, H. Ulrich-Pur, K. Schmid, M. Raderer, K. Haider, W. Kwasny, D. Depisch, B. Schneeweiss, F. Lang, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial Ann. Onc., January 1, 2003; 14(1): 97 - 104. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				C. J. Dunton Management of Treatment-Related Toxicity in Advanced Ovarian Cancer Oncologist, October 1, 2002; 7(90005): 11 - 19. [Abstract] [Full Text] [PDF]

				M. J. Egorin, E. G. Zuhowski, C. M. McCully, S. M. Blaney, J. Z. Kerr, S. L. Berg, and F. M. Balis Pharmacokinetics of Intrathecal Gemcitabine in Nonhuman Primates Clin. Cancer Res., July 1, 2002; 8(7): 2437 - 2442. [Abstract] [Full Text] [PDF]

				M. L. Hensley, R. Maki, E. Venkatraman, G. Geller, M. Lovegren, C. Aghajanian, P. Sabbatini, W. Tong, R. Barakat, and D. R. Spriggs Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial J. Clin. Oncol., June 15, 2002; 20(12): 2824 - 2831. [Abstract] [Full Text] [PDF]

				G. V. Kornek, K. Haider, W. Kwasny, M. Raderer, B. Schull, T. Payrits, D. Depisch, E. Kovats, F. Lang, and W. Scheithauer Treatment of Advanced Breast Cancer with Docetaxel and Gemcitabine with and without Human Granulocyte Colony-stimulating Factor Clin. Cancer Res., May 1, 2002; 8(5): 1051 - 1056. [Abstract] [Full Text] [PDF]

				V. Gandhi, W. Plunkett, M. Du, M. Ayres, and E. H. Estey Prolonged Infusion of Gemcitabine: Clinical and Pharmacodynamic Studies During a Phase I Trial in Relapsed Acute Myelogenous Leukemia J. Clin. Oncol., February 1, 2002; 20(3): 665 - 673. [Abstract] [Full Text] [PDF]

				H. Kusaba, T. Tamura, T. Shimoyama, K. Hotta, A. Inoue, H. Nokihara, Y. Ueda, Y. Akiyama, N. Yamamoto, I. Sekine, et al. Phase I/II Study of 3-Week Cycle Cisplatin-Gemcitabine in Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., February 1, 2002; 32(2): 43 - 47. [Abstract] [Full Text] [PDF]

				S. C. H. Chen, M.-C. Lin, J. W. C. Chang, S.-W. Wang, C.-H. Lee, and T. C. Y. Tsao Phase II Study of Regimen of Gemcitabine and Cisplatin in Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., November 1, 2000; 30(11): 494 - 498. [Abstract] [Full Text] [PDF]

				L. J. Ostruszka and D. S. Shewach The Role of Cell Cycle Progression in Radiosensitization by 2',2'-Difluoro-2'-deoxycytidine Cancer Res., November 1, 2000; 60(21): 6080 - 6088. [Abstract] [Full Text]

				K. Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, and P. A. Bunn Jr. A Phase I/II Trial of Paclitaxel, Carboplatin, and Gemcitabine in Untreated Patients with Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., September 1, 2000; 6(9): 3474 - 3479. [Abstract] [Full Text]

				G. Perez-Manga, A. Lluch, E. Alba, J. A. Moreno-Nogueira, M. Palomero, J. Garcia-Conde, D. Khayat, and N. Rivelles Gemcitabine in Combination With Doxorubicin in Advanced Breast Cancer: Final Results of a Phase II Pharmacokinetic Trial J. Clin. Oncol., July 1, 2000; 18(13): 2545 - 2552. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, R.-P. Perng, K.-Y. Yang, T.-W. Liu, C.-M. Tsai, J. Ming-Liu, and J. Whang-Peng A Multicenter Phase II Trial of Vinorelbine Plus Gemcitabine in Previously Untreated Inoperable (Stage IIIB/IV) Non-small Cell Lung Cancer Chest, June 1, 2000; 117(6): 1583 - 1589. [Abstract] [Full Text] [PDF]

				N. Masuda, K. Matsui, N. Yamamoto, T. Nogami, K. Nakagawa, S. Negoro, K. Takeda, N. Takifuji, M. Yamada, S. Kudoh, et al. Phase I Trial of Oral 2'-Deoxy-2'-methylidenecytidine: On a Daily 14-day Schedule Clin. Cancer Res., June 1, 2000; 6(6): 2288 - 2294. [Abstract] [Full Text]

				D. Pectasides, A. Aspropotamitis, A. Halikia, A. Visvikis, F. Antoniou, A. Kalantaridou, N. Karvounis, S. Batzios, and A. Athanassiou Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase II Study J. Clin. Oncol., December 1, 1999; 17(12): 3816 - 3821. [Abstract] [Full Text] [PDF]

				L. Crino, G. V. Scagliotti, S. Ricci, F. De Marinis, M. Rinaldi, C. Gridelli, A. Ceribelli, R. Bianco, M. Marangolo, F. Di Costanzo, et al. Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project J. Clin. Oncol., November 1, 1999; 17(11): 3522 - 3530. [Abstract] [Full Text] [PDF]

				J. E. Groopman and L. M. Itri Chemotherapy-Induced Anemia in Adults: Incidence and Treatment J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634. [Abstract] [Full Text] [PDF]

				G. Frasci, N. Panza, P. Comella, G. P. Nicolella, M. Natale, L. Manzione, D. Bilancia, R. Cioffi, L. Maiorino, G. De Cataldis, et al. Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study J. Clin. Oncol., August 1, 1999; 17(8): 2316 - 2316. [Abstract] [Full Text] [PDF]

				A. Sandler and D. S. Ettinger Gemcitabine: Single-Agent and Combination Therapy in Non-Small Cell Lung Cancer Oncologist, June 1, 1999; 4(3): 241 - 251. [Abstract] [Full Text]

				V. Georgoulias, C. Kouroussis, N. Androulakis, S. Kakolyris, M.-A. Dimopoulos, E. Papadakis, D. Bouros, F. Apostolopoulou, C. Papadimitriou, A. Agelidou, et al. Front-Line Treatment of Advanced Non–Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial J. Clin. Oncol., March 1, 1999; 17(3): 914 - 914. [Abstract] [Full Text] [PDF]

				R. V. Iaffaioli, A. Tortoriello, G. Facchini, F. Caponigro, M. Gentile, N. Marzano, A. Gravina, P. Dimitri, G. Costagliola, A. Ferraro, et al. Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non–Small-Cell Lung Cancer J. Clin. Oncol., March 1, 1999; 17(3): 921 - 921. [Abstract] [Full Text] [PDF]

				F. Cardenal, M. P. Lopez-Cabrerizo, A. Anton, V. Alberola, B. Massuti, A. Carrato, I. Barneto, M. Lomas, M. Garcia, P. Lianes, et al. Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer J. Clin. Oncol., January 1, 1999; 17(1): 12 - 12. [Abstract] [Full Text] [PDF]

				C. J.A. van Moorsel, G. J. Peters, and H. M. Pinedo Gemcitabine: Future Prospects of Single-Agent and Combination Studies Oncologist, June 1, 1997; 2(3): 127 - 134. [Abstract] [Full Text] [PDF]

				{blacktriangledown}Gemcitabine for lung cancer DTB, September 1, 1996; 34(9): 71 - 72. [Abstract] [Full Text] [PDF]